Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Daewoong Pharmaceutical Co., Ltd. (069620) Price & Analysis

069620 Stock Chart & Stats

$101,100.00-$400.00(-0.39%)
At close: 4:00 PM EDT
$100,000$110,000$120,000$130,0003 Aug18 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$98,400.00 - $101,900.00
52-Week Range
$98,400.00 - $199,400.00
Previous Close
$101,500.00
Volume
N/A
Average Volume (3M)
16.51K
Market Cap
KRW 1.16T
Enterprise Value
KRW 2.19T
Total Cash (Recent Filing)
KRW 158.42B
Total Debt (Recent Filing)
KRW 925.02B
Price to Earnings (P/E)
6.0
Beta
0.10
Next Earnings
Nov 12, 2026
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
0.59%

Bulls Say, Bears Say

Bulls Say

Revenue And Margin Growth

Sustained revenue expansion alongside gross margins above 50% and a sharp recovery in net margin indicates stronger recent operating performance. This supports reinvestment in pharmaceutical development, expands the earnings base, and may improve the company’s ability to compete across domestic and international markets.

Improving Operating Cash Flow

The substantial rebound in operating cash flow shows that the business is converting more of its activity into cash than during 2024. Although free cash flow remains negative, stronger operating inflows provide a better foundation for funding operations and reducing reliance on external financing over coming periods.

Strengthened Governance

Reappointing an independent audit committee member strengthens oversight and brings the company into alignment with amended governance requirements. More robust audit supervision can improve accountability, support regulatory compliance, and provide a durable governance foundation for a pharmaceutical business managing development and commercialization risks.

Bears Say

Rising Leverage

Debt has increased materially faster than the earlier balance-sheet base, leaving borrowings at roughly 0.87 times equity in the latest period. This reduces financial flexibility if profitability weakens, increases the importance of successful cash conversion, and can constrain investment or capital-allocation choices.

Persistently Negative Free Cash Flow

Repeatedly negative free cash flow indicates that investment and capital spending continue to consume more cash than the business generates after operations. That gap can require additional borrowing or other funding, raising sustainability risk and limiting the company’s ability to finance growth internally.

Earnings Volatility

The sharp deterioration in profitability during 2024 followed by a strong recovery demonstrates that earnings are not consistently stable. Such volatility can reflect changing costs, product mix, or investment cycles, making future profit conversion harder to predict and increasing sensitivity to operational execution.

Daewoong Pharmaceutical Co., Ltd. News

069620 FAQ

What was Daewoong Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Daewoong Pharmaceutical Co., Ltd. lowest stock price was $98400.00 and its highest was $199400.00 in the past 12 months.
What is Daewoong Pharmaceutical Co., Ltd.’s market cap?
Daewoong Pharmaceutical Co., Ltd.’s market cap is ₩1.16T.
When is Daewoong Pharmaceutical Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Daewoong Pharmaceutical Co., Ltd.’s earnings last quarter?
Daewoong Pharmaceutical Co., Ltd. released its earnings results on Aug 14, 2026. The company reported $2,899.861 earnings per share for the quarter.
Is Daewoong Pharmaceutical Co., Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Daewoong Pharmaceutical Co., Ltd. pay dividends?
Daewoong Pharmaceutical Co., Ltd. pays a ― dividend of $600 which represents an annual dividend yield of 0.59%. See more information on Daewoong Pharmaceutical Co., Ltd. dividends here
What is Daewoong Pharmaceutical Co., Ltd.’s EPS estimate?
Daewoong Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daewoong Pharmaceutical Co., Ltd. have?
Daewoong Pharmaceutical Co., Ltd. has 11,586,575 shares outstanding.
What happened to Daewoong Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Daewoong Pharmaceutical Co., Ltd. reported an EPS of $2,899.861 in its last earnings report. Following the earnings report the stock price went up 1.054%.
Which hedge fund is a major shareholder of Daewoong Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in KR:069620
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology